TTC Oncology
Business Services · 11-50 Employees
View Company Info for Free
Overview
Phone Number
(952) 484-1017Website
www.ttconcology.comRevenue
$5.6 MillionIndustry
About TTC Oncology
TTC Oncology Org Chart
Is TTC Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if TTC Oncology had a recent Job posting/layoffs
TTC Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on TTC Oncology recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if TTC Oncology is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at TTC Oncology
Check if TTC Oncology has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when TTC Oncology launches new products
Funding: Get notified immidiatlly once TTC Oncology has new funding data
Recommended Actions
Find VP level buyers at TTC Oncology
Find 2 more new buyers
Compare Similar Companies to TTC Oncology
Compare insights from companies similar to TTC Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TTC Oncology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TTC Oncology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TTC Oncology.
TTC Oncology Tech Stack
A closer look at the technologies used by TTC Oncology
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TTC Oncology
TTC Oncology LLC, founded in July 2015, focuses on innovating safer solutions for the treatment of metastatic breast cancer. The company holds a worldwide license from the University of Illinois Chicago for a novel composition aimed at therapeutic modulation of the estrogen receptor in ER+ breast cancer. Directed by equity-owning members and suppor... Read More